<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03561779</url>
  </required_header>
  <id_info>
    <org_study_id>YY_YYD302_003</org_study_id>
    <nct_id>NCT03561779</nct_id>
  </id_info>
  <brief_title>Clinical Trial of YYD302 (Phase3) for Treatment of Osteoarthritis of the Knee</brief_title>
  <official_title>A Randomized, Double-blind, Active-controlled, Multi-center, Phase 3 Study to Evaluated the Safety and Efficacy of Intraarticular Hyalurinic Acid(YYD302) for Osteoarthritis of the Knee After 12 Weeks of Treatment and Retreatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yooyoung Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yooyoung Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, active-controlled, multi-center, phase 3 study to&#xD;
      evaluate the safety and efficacy of intraarticular hyaluronic acid(YYD302) for osteoarthritis&#xD;
      of the knee after 12 weeks of treatment and retreatment&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      First Injection: A multicenter, active-controlled, randomized, evaluator and subject&#xD;
      bllinded, parallel, phase 3 study Re-Injection: A multicenter, active-controlled, randomized,&#xD;
      parallel&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 21, 2018</start_date>
  <completion_date type="Actual">October 4, 2019</completion_date>
  <primary_completion_date type="Actual">June 14, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The Subjects are injected investigational Product (YYD302 or Synovian Inj.)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of change of the Weight-bearing pain(100mm-VAS) on 12 weeks after first injection in comparison with baseline</measure>
    <time_frame>Change of the week 12 from baseline</time_frame>
    <description>Weight-bearing pain(100mm-VAS) assessed by the subject</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of change of the Weight-bearing pain(100mm-VAS) on 2, 4 weeks after administration in comparison with baseline</measure>
    <time_frame>Change of the week 2, 4 from baseline</time_frame>
    <description>Weight-bearing pain(100mm-VAS) assessed by the subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change of the KOOS scales on the 2, 4, 12 weeks after administration in comparison with baseline</measure>
    <time_frame>Change of the week 2, 4, 12 from baseline</time_frame>
    <description>KOOS scales assessed by the subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change of the rest pain(100mm-VAS) on the 2, 4, 12 weeks after administration in comparison with baseline</measure>
    <time_frame>Change of the week 2, 4, 12 from baseline</time_frame>
    <description>Rest pain(100mm-VAS) assessed by the subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change of the Motion pain (100mm-VAS) on the 2, 4, 12 weeks after administration in comparison with baseline</measure>
    <time_frame>Change of the week 2, 4, 12 from baseline</time_frame>
    <description>Motion pain(100mm-VAS) assessed by the subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient global assessment (100mm-VAS) on the 2, 4, 12 weeks after administration with baseline</measure>
    <time_frame>Change of the week 2, 4, 12 from baseline</time_frame>
    <description>Patient global assessment (100mm-VAS) assessed by the subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator global assessment (100mm-VAS) on the 2, 4, 12 weeks after administration with baseline</measure>
    <time_frame>Change of the week 2, 4, 12 from baseline</time_frame>
    <description>Patient global assessment (100mm-VAS) assessed by the investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the swelling in the knee joint from baseline to 2, 4, 12 weeks after administration</measure>
    <time_frame>Change of the week 2, 4, 12 from baseline</time_frame>
    <description>Sweeling assessed by the investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the tenderness on pressure in the knee joint from baseline to 2, 4, 12 weeks after administration</measure>
    <time_frame>Change of the week 2, 4, 12 from baseline</time_frame>
    <description>Tenderness on pressure assessed by the investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of the Range Of Motion(ROM) in the knee joint on 2, 4, 12 weeks after administration with baseline</measure>
    <time_frame>Change of the week 2, 4, 12 from baseline</time_frame>
    <description>Range of motion assessed by the investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder rate of the Weight-bearing pain on 12 weeks in comparison with baseline</measure>
    <time_frame>Change of the week 12 from baseline</time_frame>
    <description>Responder rate of the Weight-bearing pain assessed by the investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder rate of the OMERACT-OARSI on 12 weeks in comparison with baseline</measure>
    <time_frame>Change of the week 12 from baseline</time_frame>
    <description>Responder rate of the OMERACT-OARSI assessed by the investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of rescue medication count and the total amount on each visit after injection</measure>
    <time_frame>Change of the each visit(2, 4, 12, 24, 36 weeks) after injection</time_frame>
    <description>Use of rescue medication count and the total amount assessed by subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The efficacy of secondary outcome 1~11 after 12 weeks(36weeks) compared with the Re-injection(24weeks) in re-injection subjects</measure>
    <time_frame>Change of the week 12 (36 weeks) after Re-injection(24weeks)</time_frame>
    <description>Each outcome assessed by the investigator or subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The efficacy of secondary outcome 1~11 after baseline compared with 2, 4, 12, 24, 36 weeks in Re-injection subjects</measure>
    <time_frame>Change of the week 2, 4, 12, 24, 36 from baseline</time_frame>
    <description>Each outcome assessed by the investigator or subject</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">184</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>YYD302</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>YYD302 (2ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Synovian Inj.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Synovian Inj. (3ml)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YYD302 2ml</intervention_name>
    <description>YYD302 2ml</description>
    <arm_group_label>YYD302</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active comparator: Synovian Inj.</intervention_name>
    <description>Active comparator: Synovian Inj.</description>
    <arm_group_label>Synovian Inj.</arm_group_label>
    <other_name>Synovian Inj.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        [Visit 1, 2 Inclusion Criteria]&#xD;
&#xD;
          1. Males or Females 40 years and older&#xD;
&#xD;
          2. According to the clinical diagnosis standard of the American College of Rheumatology&#xD;
             (ACR), someone, diagnosed as a single/both sides of osteoarthritis, who corresponds to&#xD;
             over 3 conditions of followings.&#xD;
&#xD;
        1) Over 50 years of age 2) Less than 30 minutes of morning stiffness 3) Crepitus on active&#xD;
        motion 4) 4 bony tenderness 5) Bony enlargement 6) Nopalpable warmth of synvium 3. Within 6&#xD;
        months from screening visit, someone who diagnosed with Kellgren &amp; Lawrence Grade I~III by&#xD;
        the radioactive examination.&#xD;
&#xD;
        4. By the Weight-bearing pain(100mm-VAS) examination, someone who has a outcome of the&#xD;
        single or both sides of the osteoarthritis is over 40mm 5. Patient (No-responder) who has&#xD;
        experienced steady pain in spite of dosing NSAIDs or other pain-killers in the past.&#xD;
&#xD;
        6. Patient who can walk by themselves without helper like cane or walker etc. (If the&#xD;
        patient who has used helper routinely from previous 6 months, evaluating the patient&#xD;
        including the helper is possible. In this case, patient needs to use same helper&#xD;
        continuously by end of the clinical trial test.) 7. Patient who agrees to participate in&#xD;
        this clinical trial by themselves.&#xD;
&#xD;
        [Visit 6, 7 Inclusion criteria] 1. According to the clinical diagnosis standard of the&#xD;
        American College of Rheumatology (ACR), someone, diagnosed as a single/both sides of&#xD;
        osteoarthritis, who corresponds to over 3 conditions of followings.&#xD;
&#xD;
          1. Over 50 years of age&#xD;
&#xD;
          2. Less than 30 minutes of morning stiffness&#xD;
&#xD;
          3. Crepitus on active motion&#xD;
&#xD;
          4. 4 bony tenderness&#xD;
&#xD;
          5. Bony enlargement&#xD;
&#xD;
          6. Nopalpable warmth of synvium 2. At Re-screening visit, someone who diagnosed with&#xD;
             Kellgren &amp; Lawrence Grade I~III by the radioactive examination.&#xD;
&#xD;
        3. Patient who can walk by themselves without helper like cane or walker etc. (If the&#xD;
        patient who has used helper routinely from previous 6 months, evaluating the patient&#xD;
        including the helper is possible. In this case, patient needs to use same helper&#xD;
        continuously by end of the clinical trial test.) 4. Patient who are confirmed for Responder&#xD;
        by efficacy at visit 5.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Someone who has BMI≥32kg/m² at the screening visit.&#xD;
&#xD;
          2. Patient who has an experience dosing psychoactive drug, narcotic analgesic which can&#xD;
             have an effect on pain sense over 3 months habitually.&#xD;
&#xD;
          3. Patient who has been administrated gastrointestinal drug(for example H₂-blockers,&#xD;
             misoprostol or proton pump inhibitors) regularly, who can't stop injecting for&#xD;
             clinical study period.&#xD;
&#xD;
          4. Patient has attended abnormal values from screening test(2 times excess at upper limit&#xD;
             of the normal values at ALT, AST, BUN, Serum Creatinine).&#xD;
&#xD;
          5. Patient who has rheumarthritis or other inflammatory metabolic arthritis.&#xD;
&#xD;
          6. Patients having serious gastrointestinal, liver, renal, heart disease.&#xD;
&#xD;
          7. When the inflammatory disease is occurred on joint area to patient like septic&#xD;
             arthritis.&#xD;
&#xD;
          8. Patients having skin ailment at the injecting site of the joint region.&#xD;
&#xD;
          9. Patients having secondary osteoarthritis according to the Ochronosis, Hemochromatosis&#xD;
             or systemic disease.&#xD;
&#xD;
         10. Patients who have severe pain like Sudek's atrophy, Paget's disease, Spinal disc&#xD;
             herniation.&#xD;
&#xD;
         11. Poly-articular patients who have suffered seriously by osteoarthritis at other parts&#xD;
             affect judge of the knee joint pain.&#xD;
&#xD;
         12. Patients who diagnosed clear interval disappearance at the knee joint by X-ray.&#xD;
&#xD;
         13. Patients who were administrated below drugs before baseline visit. 1) Patients who&#xD;
             were injected HA at the target knee joint or other parts of knee joint in recent 9&#xD;
             months.&#xD;
&#xD;
        2) Patients who were injected steroids into the intra-articular knee joint in recent 3&#xD;
        months 3) Patients who were administrated steroids systemically by the oral medication&#xD;
        (But, except inhalation) 4) Patients who were administerated Osteoarthritis nutrition such&#xD;
        as glucosamine/chondroichin sulfate or physical therapy or herbal remedy(acupuncture,&#xD;
        yellowish swelling, moxa cautery) for the purpose of pain relief in recent 2 weeks 5)&#xD;
        Patients who have administerated steroid/No-steriod NSAIDs or other pain relief drugs&#xD;
        (patch or other external medicine) in recents 2 weeks except Acetaminophen or below&#xD;
        300mg/day of Asprin 14. Patients who have joint effusion trouble were judged as a positive&#xD;
        by tests like Patella tap test.&#xD;
&#xD;
        15. Patients who have target knee joint gotten surgical operation history including&#xD;
        Arthroscopy within past one year (In case of having other side of knee joint or hip joint&#xD;
        gotten surgical operation history, excepting the patients if there is possibility which can&#xD;
        influence the target knee joint's appraisal.&#xD;
&#xD;
        16. Patients who have an operation history about target knee joint. 17. Patients who do the&#xD;
        height weight aerobic exercise or anaerobic exercise. 18. Patients who need to be&#xD;
        administrated anticoagulant agent together(But, except 300mg daily dose aspirin) 19.&#xD;
        Patients who have hypersensitivity history about Investigational Product.&#xD;
&#xD;
        20. In the midst of women in their childbearing years, patients who disagree to do *&#xD;
        contraception by medically permitted method for 12 weeks from administrating&#xD;
        investigational product.&#xD;
&#xD;
          -  The contraception by medically permitted method: Condom, In case of using injection or&#xD;
             insertion, In case of installing a intrauterine contraception device etc.&#xD;
&#xD;
             21. Pregnant and lactating women 22. Patients who were injected other investigational&#xD;
             product over a time within 30 days before participated in this clinical trail.&#xD;
&#xD;
             23. Besides that, the patients who have difficulty to be participated in this clinical&#xD;
             trial continuously by Principle Investigator (PI)'s decision.&#xD;
&#xD;
          -  Exclusion criteria for Re-injection is except for 13-1) Re-injection date is followed&#xD;
             by visit 7.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chul-Won Ha, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center, Department of Internal Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 4, 2018</study_first_submitted>
  <study_first_submitted_qc>June 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2018</study_first_posted>
  <last_update_submitted>May 7, 2021</last_update_submitted>
  <last_update_submitted_qc>May 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

